Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914055825> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2914055825 abstract "Background Walking impairment is one of the major primary symptoms in patients with multiple sclerosis (MS), which greatly affects their quality of life and emotional state. Fampridine is a new oral treatment used to improve walking ability in adults with MS. Its use was approved by the EMA in 2011 for patients with an Expanded Disability Status Scale (EDSS) score between 4 and 7. Patients who do not experience clinical benefits (reported by the physician and patient) after two weeks’ treatment should discontinue fampridine. This condition was established due to the results of Phase III trials, which demonstrated improved walking ability in only 35–43% of the patients treated with fampridine and an increase in absolute walking speed in 20% of the patients. Purpose To evaluate the effectiveness of sustained-release fampridine in patients with MS and walking disability, after 2 weeks of treatment. Material and methods A one-year prospective, observational study. Patient characteristics (age, sex), clinical data (EDSS, clinical benefits perceived by the physician and patient) and treatment-related information (drug, dose and number of tablets dispensed) were obtained from the available databases in our hospital. Results 91 patients started taking fampridine between October 2013 (when the Pharmacy Commission approved its use in our hospital) and October 2014. They were reviewed after two weeks of treatment by their neurologist and pharmacist to evaluate improvement in their walking ability and physical condition. In this reassessment, 71 patients (78%) showed an improvement in their walking ability and moving speed, and continued the treatment. Only 18 of these (25%) experienced a reduction of their EDSS (mean 0.5 points). None of them suffered adverse effects due to fampridine. Conclusion Our patients responded better than anticipated from the clinical trials. Although fampridine has shown limited efficacy it covers a current treatment gap in this disease. References and/or acknowledgements No conflict of interest." @default.
- W2914055825 created "2019-02-21" @default.
- W2914055825 creator A5039838330 @default.
- W2914055825 creator A5041666368 @default.
- W2914055825 creator A5078772027 @default.
- W2914055825 date "2015-03-01" @default.
- W2914055825 modified "2023-09-27" @default.
- W2914055825 title "DI-022 New chances in multiple sclerosis treatment: sustained-release fampridine" @default.
- W2914055825 doi "https://doi.org/10.1136/ejhpharm-2015-000639.200" @default.
- W2914055825 hasPublicationYear "2015" @default.
- W2914055825 type Work @default.
- W2914055825 sameAs 2914055825 @default.
- W2914055825 citedByCount "0" @default.
- W2914055825 crossrefType "journal-article" @default.
- W2914055825 hasAuthorship W2914055825A5039838330 @default.
- W2914055825 hasAuthorship W2914055825A5041666368 @default.
- W2914055825 hasAuthorship W2914055825A5078772027 @default.
- W2914055825 hasConcept C104863432 @default.
- W2914055825 hasConcept C118552586 @default.
- W2914055825 hasConcept C126322002 @default.
- W2914055825 hasConcept C159110408 @default.
- W2914055825 hasConcept C1862650 @default.
- W2914055825 hasConcept C23131810 @default.
- W2914055825 hasConcept C2779457091 @default.
- W2914055825 hasConcept C2779951463 @default.
- W2914055825 hasConcept C2780640218 @default.
- W2914055825 hasConcept C2780892749 @default.
- W2914055825 hasConcept C512399662 @default.
- W2914055825 hasConcept C535046627 @default.
- W2914055825 hasConcept C70770792 @default.
- W2914055825 hasConcept C71924100 @default.
- W2914055825 hasConceptScore W2914055825C104863432 @default.
- W2914055825 hasConceptScore W2914055825C118552586 @default.
- W2914055825 hasConceptScore W2914055825C126322002 @default.
- W2914055825 hasConceptScore W2914055825C159110408 @default.
- W2914055825 hasConceptScore W2914055825C1862650 @default.
- W2914055825 hasConceptScore W2914055825C23131810 @default.
- W2914055825 hasConceptScore W2914055825C2779457091 @default.
- W2914055825 hasConceptScore W2914055825C2779951463 @default.
- W2914055825 hasConceptScore W2914055825C2780640218 @default.
- W2914055825 hasConceptScore W2914055825C2780892749 @default.
- W2914055825 hasConceptScore W2914055825C512399662 @default.
- W2914055825 hasConceptScore W2914055825C535046627 @default.
- W2914055825 hasConceptScore W2914055825C70770792 @default.
- W2914055825 hasConceptScore W2914055825C71924100 @default.
- W2914055825 hasLocation W29140558251 @default.
- W2914055825 hasOpenAccess W2914055825 @default.
- W2914055825 hasPrimaryLocation W29140558251 @default.
- W2914055825 hasRelatedWork W1964716895 @default.
- W2914055825 hasRelatedWork W2023901085 @default.
- W2914055825 hasRelatedWork W2061781446 @default.
- W2914055825 hasRelatedWork W2078067833 @default.
- W2914055825 hasRelatedWork W2123509369 @default.
- W2914055825 hasRelatedWork W2320839113 @default.
- W2914055825 hasRelatedWork W2328917992 @default.
- W2914055825 hasRelatedWork W2559173389 @default.
- W2914055825 hasRelatedWork W2561248206 @default.
- W2914055825 hasRelatedWork W2626333776 @default.
- W2914055825 hasRelatedWork W2765875427 @default.
- W2914055825 hasRelatedWork W2778157767 @default.
- W2914055825 hasRelatedWork W2891917869 @default.
- W2914055825 hasRelatedWork W2898638003 @default.
- W2914055825 hasRelatedWork W2899534382 @default.
- W2914055825 hasRelatedWork W3009204078 @default.
- W2914055825 hasRelatedWork W3046210129 @default.
- W2914055825 hasRelatedWork W3140944371 @default.
- W2914055825 hasRelatedWork W3174285549 @default.
- W2914055825 hasRelatedWork W3180192029 @default.
- W2914055825 isParatext "false" @default.
- W2914055825 isRetracted "false" @default.
- W2914055825 magId "2914055825" @default.
- W2914055825 workType "article" @default.